TD Treatment

The Recommended Treatment Guidelines

The 2020 American Psychological Association (APA) Practice Guideline recommends that patients with moderate-to-severe or disabling tardive dyskinesia (TD) be treated with a VMAT2 inhibitor. Patients with mild TD also can be treated, based on their preference or impairment, or the effect of their TD on psychosocial functioning. Anticholinergics are not approved to treat TD and may make the symptoms worse.¹

Actor portrayals.

Explore the case studies below

Consider whether a VMAT2 inhibitor would be a suitable treatment option for these and similar patients.

Tardive Dyskinesia- 70-Year-Old woman with tardive dyskinesia (TD) showing oro-buccal-lingual stereotypy, toe tapping, and finger movements

Interactive
•
~5 mins
•
Dec 2022

Tardive Dyskinesia: A Look Into My Practice
Presentation
•
~2 mins
•
Oct 2022

Guidelines and Consensus on Screening and Treatment of Tardive Dyskinesia
Video
•
10+ mins
•
Jan 2025

A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia

Explore the full library

Talk to your patients about managing their TD

There are treatments available.

Learn about an option for your TD patients

Reference

American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association; 2021.

The Recommended Treatment Guidelines

Explore the case studies below

Spotlight on Treating TD

Talk to your patients about managing their TD